September 2026 Options Now Available For Gilead Sciences (GILD)

Analysis of Gilead Sciences (GILD) options reveals potential YieldBoost opportunities for investors. Selling a $105 put offers a 12.57% return if it expires worthless, with a 61% probability based on current analytics, while a covered call strategy at $110 could yield 16.12% if the stock is called away; if it expires worthless, the investor would receive a 12.48% boost. The implied volatility for the put and call options are 34% and 32% respectively, while the trailing twelve month volatility is 27%.

Analysis

The article outlines two specific options strategies for Gilead Sciences (GILD), which is currently trading at $106.14 per share. One strategy involves selling a put contract at the $105.00 strike price, with a current bid of $13.20. This action commits the seller to purchase GILD at $105.00 if exercised, but the collected premium reduces the effective cost basis to $91.80 per share, representing an attractive entry point for investors already interested in the stock. This put option, approximately 1% out-of-the-money, has a 61% probability of expiring worthless, which would yield a 12.57% return on the cash commitment, or an annualized YieldBoost of 9.50%. The second strategy is a covered call, where an investor purchasing GILD at $106.14 simultaneously sells a $110.00 strike call contract (expiring September 2026) for a $13.25 premium. This could result in a 16.12% total return if the stock is called away at $110.00. If this call, which is approximately 4% out-of-the-money, expires worthless (a 44% probability), the investor keeps the shares and the premium, achieving a 12.48% return boost, or an annualized YieldBoost of 9.43%. The implied volatility for the put is 34% and for the call is 32%, both notably higher than GILD's actual trailing twelve-month volatility of 27%, suggesting that option premiums are currently relatively rich compared to recent realized price movements.

Key Decisions for Investors

• Investors considering initiating a position in Gilead Sciences and comfortable with acquiring shares at $105.00 could evaluate selling the described put option to achieve a lower effective cost basis of $91.80 or generate a 9.50% annualized yield if the option expires unexercised.
• Current Gilead Sciences shareholders could assess the suitability of the $110 strike covered call strategy for the September 2026 expiration to potentially generate additional income, targeting a 16.12% return if called or a 9.43% annualized yield enhancement if the option expires worthless, while acknowledging the cap on upside potential beyond the strike price.
• Given that the implied volatilities of 32-34% for the discussed GILD options exceed the stock's 27% trailing twelve-month historical volatility, strategies involving selling options may offer enhanced premium capture opportunities at present.